Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 3

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3Sarcoma 2

Conditions

Lung Neoplasms 28Ovarian Neoplasms 27Fallopian Tube Neoplasms 24Carcinoma, Non-Small-Cell Lung 21Colorectal Neoplasms 17Glioblastoma 11Pancreatic Neoplasms 10Melanoma 10Carcinoma, Renal Cell 10Carcinoma, Hepatocellular 10Breast Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Lymphoma, Large B-Cell, Diffuse 8Urinary Bladder Neoplasms 7Neoplasm Metastasis 7Colonic Neoplasms 7Brenner Tumor 7Uterine Cervical Neoplasms 6Rectal Neoplasms 6Prostatic Neoplasms 6Mycosis Fungoides 6Leukemia, Lymphocytic, Chronic, B-Cell 6Brain Neoplasms 6Triple Negative Breast Neoplasms 5Multiple Myeloma 5Lymphoma, T-Cell, Cutaneous 5Sezary Syndrome 4Sarcoma 4Neoplasms 4Nasopharyngeal Carcinoma 4

Interventions

Temozolomide 73Radiotherapy 33Carboplatin 21Bevacizumab 18Irinotecan 16Carmustine 16Magnetic Resonance Spectroscopy 15Vincristine 14Surgical Procedures, Operative 13Filgrastim 13Procarbazine 10Erlotinib Hydrochloride 8Cyclophosphamide 8Peripheral Blood Stem Cell Transplantation 7O(6)-benzylguanine 7Lomustine 7Etoposide 7sargramostim 6Imatinib Mesylate 6Flucytosine 6Cisplatin 62-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 6temsirolimus 5Vorinostat 5Thiotepa 5Radiotherapy, Intensity-Modulated 5Radiation 5Biopsy 52,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 5vocimagene amiretrorepvec 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Oligodendroglioma × Disulfides × Clear all
NCT01609790 2022-07-21

Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors

National Cancer Institute (NCI)

Phase 2 Completed
137 enrolled 13 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Oligodendroglioma, Gliosarcoma

NCT01648348 2018-05-23

Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme

National Cancer Institute (NCI)

Phase 1/2 Completed
116 enrolled 17 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

NCT00381797 2017-11-28

Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma

National Cancer Institute (NCI)

Phase 2 Completed
97 enrolled 35 charts
CNS

Familial ependymoma, Medulloblastoma, Oligodendroglioma, Spinal Cord Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡